Serum IL-18 is a specific biomarker for Macrophage Activation Syndrome across several autoinflammatory diseases by unknown
POSTER PRESENTATION Open Access
Serum IL-18 is a specific biomarker for
Macrophage Activation Syndrome across several
autoinflammatory diseases
SW Canna1*, AA de Jesus1, G Shi2, Y Huang1, GA Montealegre Sanchez1, I Gery2, R Goldbach-Mansky1
From 8th International Congress of Familial Mediterranean Fever and Systemic Autoinflammatory Diseases
Dresden, Germany. 30 September - 3 October 2015
Question
IL-18 is a pro-inflammatory cytokine produced by a
variety of myeloid and non-hematopoietic cells. It is
canonically associated with enhancing interferon gamma
(IFNg) and cytotoxicity in collaboration with IL-12p70,
IL-15, or type I IFN. However, in other contexts IL-18
can promote IL-17, IL-22, or allergic responses. Macro-
phage Activation Syndrome (MAS) is a sepsis-like syn-
drome that has been associated with elevated serum
IL-18 in systemic Juvenile Idiopathic Arthritis, Stills dis-
ease, and XIAP-deficiency. We sought to characterize
IL-18 and associated cytokines in a cohort of patients
with a variety of monogenic or complex autoinflamma-
tory syndromes.
Methods
Serum IL-18 was measured across several platforms and
normalized to healthy controls run in the same batch.
For many patients, IL-18 binding protein (IL-18BP) and
IL-37 were measured from the same sample. Results
were correlated with clinical laboratory findings, most
notably acute phase reactants like C-reactive protein
and erythrocyte sedimentation rate obtained on the
same date.
Results
We found three patterns of serum IL-18: 1) normal
IL-18 in healthy controls, patients with STING muta-
tions, patients with chronic non-bacterial osteomyelitis
(CNO), and patients with deficiency of IL-1 receptor
antagonist (DIRA); 2) Mild elevation (less than 10-fold
above normal) of serum IL-18 in patients with defects
in NLRP3 (Cyropyrin Associated Periodic Syndromes,
CAPS) or proteasomal defects (Chronic Atypical Neu-
trophilic Dermatosis Lipodystrophy Elevated Tempera-
ture, CANDLE); and 3) extraordinary elevation (100 to
500 fold above normal) in patients with a history of
MAS regardless of disease activity. Multiple serial IL-18
measurements were made in a patient harboring an
NLRC4 mutation, as well as a patient with clinical
NOMID (including severe epiphyseal overgrowth) with
no detectable germ-line or somatic gene defect who had
multiple severe MAS episodes. There are two endogen-
ous antagonists of IL-18: IL-18BP and IL-37. These
cytokines correlated moderately with CRP, but not with
serum IL-18.
Conclusions
Our data suggest that extreme elevation of serum IL-18,
particularly in the absence of acute inflammation, is a
unique biomarker for MAS risk across many autoin-
flammatory phenotypes. The mechanisms by which
chronic elevation of IL-18 may promote the MAS phe-
notype need to be further investigated.
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